Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOPE-3: Rosuvastatin and Candesartan/HCT for Cardiovascular Prevention
NCT00468923Phase 4Completed
- Sponsor
- Population Health Research Institute
- Start
- May 2007
- Primary completion
- Dec 2015
- Modality
- Orthosteric Ligands, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rosuvastatin, candesartan, hydrochlorothiazide in cardiovascular disease (CVD), stroke, sponsored by Population Health Research Institute. Started May 2007; status: completed.
02
Drugs
rosuvastatincandesartanhydrochlorothiazide
03
Conditions
cardiovascular disease (CVD)stroke
Beyond the preview
Go deeper on NCT00468923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00468923.